Kyverna Therapeutics Inc's Customers Performance

Name: Kyverna Therapeutics Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

KYTX

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


KYTX's Source of Revenues		• List of KYTX Customers

for the same period Kyverna Therapeutics Inc

• List of KYTX Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Kyverna Therapeutics Inc's Comment on Sales, Marketing and Customers

News about Kyverna Therapeutics Inc Contracts

Class Action Looms Over Kyverna Therapeutics, Inc. with February Deadline for Lead Plaintiffs

In a significant development for stakeholders of Kyverna Therapeutics, Inc. investors are being alerted to an impending class action lawsuit against the company. Levi and Korsinsky, LLP, a prominent securities litigation firm, has issued a notice to investors regarding the class action lawsuit, urging them to be aware of a critical deadline. The legal proceedings come with a lead plaintiff deadline set for February 7, 2025. Kyverna Therapeutics, Inc. publicly traded on the NASDAQ under the ticker symbol KYTX, has found itself at the center of this legal matter amidst challenging market conditions. As of the writing of this article, the company s stock price stands at a mere $3.99, reflecting broader concerns...

Kyverna Therapeutics Investors Advised to Seek Counsel Ahead of Securities Class Action Deadline

In a recent development significant to investors in the biotechnology sector, Rosen Law Firm, a prominent global investor rights law firm, has issued a reminder to those who purchased common stock of Kyverna Therapeutics, Inc. (NASDAQ: KYTX). The firm emphasizes that these investors, whose stock purchases are pursuant and/or traceable to the company’s initial public offering conducted on February 8, 2024, are approaching an important legal deadline.Kyverna Therapeutics, Inc. known for its innovations in the field of cellular immunotherapy, became a publicly traded entity in early 2024, with an initial issuance of shares through its IPO. As of the current market assessment, the company has 43.16 million sha...

KYTX's Stock Performance relative to it's Customers

KYTX's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Kyverna Therapeutics Inc	378.78	0.00	-152.64	130
SUBTOTAL	0.00	0.00	0.00	-

Sources: Kyverna Therapeutics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Kyverna Therapeutics Inc’s corporate clients.
For your research, we’ve provided 9 tables on Kyverna Therapeutics Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.